Infusion Resilient, Kelun Biotech to be a Long-term Catalyst
发布时间:2026-10-30 来源:华泰证券
Kelun Pharma has reported 1-3Q26 revenue of RMB13.11bn (-1.2% YoY; 3Q +1.9% YoY) and the attributable net profit of RMB1.47bn (+22.2% YoY; 3Q +70% YoY, off a low base in 3Q25 when 6-APA prices at Kelun Chuanning slid). Infusion profit improved QoQ in 3Q, while Chuanning profit was constrained by demand and pricing. Considering: 1) infusion profit has bottomed, 2) Chuanning profit could improve QoQ in the seasonally strong 4Q, 3) the generic drug segment may be flattish to slightly profitable, and 4) investment income from SSY Group and others this year could be sizeable, we remain confident that core profit can reach RMB1.7bn in 2026. Maintain BUY.
Infusion: 3Q profit improved QoQ
We estimate infusion profit grew strongly YoY in 3Q26 and improved QoQ from 2Q. For 2026, we expect infusion profit to be flat YoY, driven by: 1) continued plastic bottle price recovery, with price hikes already implemented first in northern China; and 2) rapid volume growth in parenteral nutrition products, which we expect to exceed 13mn bags in 2026. The powder-liquid dual-chamber bag business renewed contracts for five essential cephalosporin products in centralized procurement, and we expect sales to surpass 30mn bags in 2026.
Chuanning under pressure, generics stable
Chuanning revenue fell 16% YoY in 1-3Q26 (3Q revenue -28% YoY, 3Q profit -65% YoY), hit by both volume and price pressure: 1) weak demand for penicillin and cephalosporin upstream intermediates/APIs weighed on 3Q shipments; and 2) prices for products such as 7-ACA declined notably YoY. For the full year, we expect Chuanning to contribute RMB300-400mn profit to Kelun, given: 1) prices have likely bottomed, and 4Q flu season could catalyze demand; and 2) we estimate synthetic biology to contribute RMB100-200mn revenue at breakeven. The non-infusion segment saw profit stabilize QoQ in 3Q, and we expect generic drug profit in 2026 to be flattish to slightly profitable after deducting platform expenses (parent company innovative drug and generic R&D spending). In addition, investment income contributed stable cash flow in 3Q (likely around RMB200mn for the full year, per our estimates).
Innovative drugs: Botai to contribute positive profit in 2026
We estimate Kelun Biotech contributed a slight loss to Kelun's profit in 3Q, but could turn positive in 2026, driven by SKB264 commercialization progress and the Yilian settlement payment. For 2026-2027, we see that: 1) 2026: ESMO OptiTROP- Lung06, OptiTROP-Lung04, and TroFuse-005 all delivered best-in-class global data that beat market expectations, with Phase III 1L TNBC data expected at SABCS in December; 2) 2027: overseas, we expect FDA approval for the EC 3L indication in 1H27 to kick off global commercialization, with late-line Phase III data for GC/NSCLC likely to be disclosed during the year and approval in 2H27; domestically, Phase III data for 1L EGFR-mutant NSCLC and 1L HR+/HER2- breast cancer are expected; 3) SKB571 is expected to initiate global Phase III in 2027 and disclose domestic Phase II data. Overall, we expect Botai's overseas sales and milestone triggers to add to Kelun's profit in 2027.
Earnings forecasts and valuation
Given volume and price pressure on some API products, we cut our 2026/2027/ 2028 attributable net profit forecasts to RMB1,823/2,409/3,110mn (previous: RMB2,057/2,674/3,257mn), implying EPS of RMB1.15/1.51/1.95 (previous: RMB1.29/1.68/2.05). We apply a 34x 2027E PE, a premium to the peer average of 33x on Wind consensus, reflecting the imminent domestic and overseas ramp-up of the company’s innovative drugs, for our target price of RMB51.34 (previous: RMB46.44, based on 36x 2026E PE).
Risks: regional pricing pressure on infusion, API and intermediate price volatility, and impact of centralized procurement on formulations.